| CAPRICOR THERAPEUTICS |
| USA |
| Gesundheit |
| US14070B3096 / A2PLU4 |
| 4LN2 (Frankfurt) / CAPR (NASDAQ) |
| FRA:4LN2, ETR:4LN2, 4LN2:GR, NASDAQ:CAPR |
| - |
| https://capricor.com/ |
|
Capricor Therapeutics Inc. is a clinical-stage biotechnology company focused on developing transformative cell and exosome-based therapeutics for rare diseases with high unmet medical needs, particularly Duchenne muscular dystrophy (DMD), which cause..
>Volltext.. |
| 1332.52 Mio. EUR |
| 1110.11 Mio. EUR |
| - |
| -101.54 Mio. EUR |
| -98.68 Mio. EUR |
| -1.99 EUR |
| 18.19 Mio. EUR |
| 90.78 Mio. EUR |
| -79.77 Mio. EUR |
| 8.28 |
| -100% |
| -94.86% |
| - |
| - |
| - |
| - |
| CAPRICOR THERAPEUTICS, CAPRICOR THERAPEUTIC |
| 17.06.26 |